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Background: Assessment of dyspnea in COPD patients relies in clinical practice on the modi-
fied Medical Research Council (mMRC) scale, whereas the Baseline Dyspnea Index (BDI) is 
mainly used in clinical trials. Little is known on the correspondence between the two methods.
Methods: Cross-sectional analysis was carried out on data from the French COPD cohort 
Initiatives BPCO. Dyspnea was assessed by the mMRC scale and the BDI. Spirometry, 
plethysmography, Hospital Anxiety-Depression Scale, St George’s Respiratory Question-
naire, exacerbation rates, and physician-diagnosed comorbidities were obtained. Correlations 
between mMRC and BDI scores were assessed using Spearman’s correlation coefficient. An 
ordinal response model was used to examine the contribution of clinical data and lung function 
parameters to mMRC and BDI scores.
Results: Data are given as median (interquartile ranges, [IQR]). Two-hundred thirty-nine COPD 
subjects were analyzed (men 78%, age 65.0 years [57.0; 73.0], forced expiratory volume in 
1 second [FEV
1
] 48% predicted [34; 67]). The mMRC grade and BDI score were, respectively, 
1 [1–3] and 6 [4–8]. Both BDI and mMRC scores were significantly correlated at the group 
level (rho =-0.67; P0.0001), but analysis of individual data revealed a large scatter of BDI 
scores for any given mMRC grade. In multivariate analysis, both mMRC grade and BDI score 
were independently associated with lower FEV
1
% pred, higher exacerbation rate, obesity, 
depression, heart failure, and hyperinflation, as assessed by the inspiratory capacity/total lung 
capacity ratio. The mMRC dyspnea grade was also associated with the thromboembolic history 
and low body mass index.
Conclusion: Dyspnea is a complex symptom with multiple determinants in COPD patients. 
Although related to similar factors (including hyperinflation, depression, and heart failure), 
BDI and mMRC scores likely explore differently the dyspnea intensity in COPD patients and 
are clearly not interchangeable.
Keywords: dyspnea, COPD, mMRC, BDI, quality of life, hyperinflation, depression, 
comorbidities
Background
COPD is a leading cause of mortality and morbidity worldwide.1 It is characterized 
by progressive airflow limitation; COPD severity was until recently mainly defined 
by the level of post-bronchodilator forced expiratory volume in 1 second (FEV
1
).2 
Dyspnea is the predominant symptom of COPD, both in stable condition and during 
exacerbations, and appears now as a major index of disease severity and a prominent 
target of treatment. Dyspnea has been shown to be weakly associated with the most 
common lung function parameters, particularly with FEV
1
,3,4 suggesting the contribu-
tion of many other factors. Comorbidities, defined as specific chronic diseases distinct, 
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and associated with COPD, are frequent in COPD and their 
importance is being increasingly recognized.5 They impact 
many aspects of the disease, and interfere with its natural 
history. For example, high rates of cardiovascular diseases 
(eg, chronic heart failure) and mood disorders (eg, anxiety 
and depression) have been reported in COPD patients5,6 and 
suggested as contributing to dyspnea.7,8
In daily practice, dyspnea level is usually measured by 
the modified Medical Research Council (mMRC) scale. 
This scale is easy to use and has a prognostic value, and 
was thus included in all simplified prognostic scores such 
as the Body mass index–airflow Obstruction–Dyspnea, 
and Exercise (BODE) index.9 Moreover, evaluation of the 
level of dyspnea by the mMRC is now used to categorize 
COPD symptomatic burden in the new Global initiative for 
chronic Obstructive Lung Disease (GOLD) recommenda-
tions and provides useful information about COPD-induced 
disability.2,10,11 However, its unidimensional structure and 
limited number of degrees are well-recognized limitations. 
Furthermore, a major disadvantage of mMRC is that it 
shows little change with therapeutic interventions. This 
led investigators to develop other tools for evaluating the 
impact of therapies on dyspnea levels. Among these tools, 
the Baseline Dyspnea Index (BDI) has been designed for 
a multidimensional assessment of dyspnea, and the cor-
responding Transition Dyspnea Index (TDI) appears to be 
much more sensitive to changes than the mMRC.3 The BDI/
TDI has been widely validated in COPD and remains the 
most frequently used questionnaire in clinical research, par-
ticularly for therapeutic trials.12–14 The correlations between 
mMRC and BDI scores for dyspnea assessment have been 
reported in two studies by Mahler et al12,15 with correlation 
coefficients between 0.61 and 0.73. However, no details were 
given on individual concordance or discrepancies between 
these two measurements.
In the present study, the mMRC and BDI scores were 
used to evaluate dyspnea in COPD patients recruited in the 
INITIATIVES BPCO cohort.16 Our goals were 1) to analyze 
the relationships between mMRC scale and BDI score and 
2) to evaluate the independent contributions of nutritional 
status, exacerbation rate, comorbidities (including anxiety-
depression), spirometry, and lung volumes to dyspnea levels, 
as assessed by mMRC vs BDI.
Methods
The INITIATIVES BPCO cohort
COPD subjects included in the present analysis were 
recruited in the INITIATIVES BPCO cohort between January 
2005 and August 2009. The INITIATIVES BPCO cohort is 
a real-world cohort of clinically and spirometry-diagnosed 
COPD patients identified in 17 pulmonary units of university 
hospitals located throughout France. Data are recorded in 
a standardized case report form but, due to the real-world 
nature of patient care, datasets do not have to be complete 
to include a patient. Only demographic characteristics and 
spirometry are mandatory. Detailed information about this 
cohort can be found in a previous report.16 Respiratory phy-
sicians prospectively recruited subjects in stable condition 
(no history of exacerbation requiring medical treatment for 
the previous 4 weeks) with a diagnosis of COPD based on 
a post-bronchodilator FEV
1
/FVC (forced vital capacity) 
ratio 70%.17 Subjects with a main diagnosis of bronchiecta-
sis, asthma, or any other significant respiratory diseases were 
carefully excluded. At the time of the analyses, the INITIA-
TIVES BPCO cohort contained data on 633 COPD subjects. 
Because our goal was to study the impact of both lung func-
tion and comorbidities on dyspnea scores, we selected sub-
jects with complete data for spirometry, plethysmography, 
comorbidities (coronary artery disease, chronic heart failure, 
thromboembolic history, diabetes, hypertension), Hospital 
Anxiety–Depression (HAD) Scale, Saint George’s Respira-
tory Questionnaire (SGRQ) score to assess health-related 
quality of life (HRQoL), and numbers of acute exacerbations 
of COPD during the previous year. The study was approved 
by the Ethics Committee of Versailles (France), and all sub-
jects provided informed written consent.
Data collection
We used a standardized characterization process that covered 
demographic data, risk factors including cumulative tobacco 
smoking, and COPD characteristics (including symptoms 
and spirometry) in stable condition. Pulmonary function 
tests were performed according to international standards,18 
and included a spirometry and an optional plethysmographic 
assessment of lung volumes. Severity of airflow obstruc-
tion was evaluated according to GOLD classification.17 
The number of acute exacerbations of COPD during the 
previous year was determined according to patient’s self-
report. Comorbidities (including congestive heart failure, 
coronary artery disease, hypertension, and diabetes mellitus) 
were identified from the patient files (physician-diagnosed 
comorbidities). Malnutrition was defined by body mass index 
(BMI) 18.5 kg/m2 and obesity by a BMI 30 kg/m2.19 
Dyspnea was assessed by the mMRC scale11 ranging from 0 to 
4 and by the French version of the BDI, previously validated 
in COPD.20 Total BDI score (0–12, 12 meaning no dyspnea) 
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and individual dimensions (functional impairment, magni-
tude of task, and magnitude of effort, all three ranging from 
0 to 4) were analyzed. The HAD scale was used to evaluate 
mood disorders. This 14-item self-questionnaire has two 
seven-item subscales for anxiety (HAD-A) and depression 
(HAD-D). Scores range from 0 to 21 for each subscale, and 
a score of 10 or higher on either subscale is closely associ-
ated with the presence of the corresponding mood disorder.21 
HRQoL was evaluated using the original SGRQ.22
statistical analysis
The normality of mMRC and BDI distribution was evaluated 
by a Shapiro–Wilk test (W ).
Univariate analysis
With qualitative variables, the values of mMRC and BDI are 
presented using median and IQR for each level of the vari-
ables, and Wilcoxon or Kruskal–Wallis tests were used.
With quantitative variables, the relations between mMRC 
and BDI scores are presented using Spearman correlation 
coefficients.
Variables of interest were age, symptoms of chronic 
bronchitis, FEV
1
, lung volumes, exacerbation frequency, 
HAD-anxiety and -depression subscores, nutritional status, 
and comorbidities including diagnosis of cardiovascular dis-
ease (chronic heart failure, coronary artery disease), venous 
thromboembolism, and diabetes.
Multivariate analysis
Stepwise ordinal logistic regressions were performed in order 
to find parameters that explain mMRC and BDI scores, using 
the LOGISTIC procedure from SAS® 9.2 statistical software, 
with a significant level of entry of 15% and a significant 
level of stay of 10% as criteria for introducing or removing 
a covariate. For each score, two stepwise regressions were 
performed:
–	 Starting from no variable.
–	 Starting from all variables.
Each time, the two stepwise regressions converged to 
the same model.
Twelve variables were used as covariates.
Lung function variables were included as continuous 
(FEV
1
% pred, FVC% pred, functional residual capacity 
[FRC]% pred) or categorical (inspiratory capacity/total 
lung capacity ratio [IC/TLC], 25% or 25%) variables. 
Comorbidities were included as individual variables. HAD-A 
and HAD-D were entered as no or significant anxiety/depres-
sion, corresponding to values 10 for each subscore. BMI 
was entered as a categorical variable (low 18.5 kg/m2; 
obesity 30 kg/m2). Our univariate analysis showed a close 
relationship between dyspnea and HRQoL. We therefore 
deliberately excluded SGRQ from our multivariate analysis, 
to unmask other contributing factors.
Results
Patients
The present analysis included 239 subjects (53 women, 186 
men) with a mean tobacco consumption of 42.6 [25; 56] pack-
years. A comparison of the 239 patients with complete data to 
the remaining subjects with incomplete data was performed. 
Subjects with complete data had a tendency toward higher 
FVC (2.82 L vs 2.71 L; P=0.08), a higher rate of symptoms 
of chronic bronchitis (81% vs 67%, P=0.0003). No other 
differences were found between included and excluded 
subjects for clinical and lung function variables. All GOLD 
spirometry grades were represented (Table 1). Previously 
diagnosed comorbidities were found across all GOLD grades. 
The mean SGRQ total score was 45.3 [31.9; 60.9]. Mean 
FEV
1
 was 48% pred [34; 67]. Median mMRC and BDI scores 
were, respectively, 1 [1; 3] and 6 [4; 8]. The distributions 
(Figure 1) of BDI and mMRC scores were non-Gaussian: for 
mMRC: W=0.899, P0.0001; for BDI: W=0.973, P=0.0002. 
The mMRC grades and BDI scores correlated (rho =-0.672; 
P0.0001) at the group level, but large variations of BDI 
values were observed for a given mMRC grade (Figure 2). 
Although correlations were also found between mMRC 
and individual BDI dimensions (functional impairment: 
rho =-0.621, P0.0001; magnitude of task: rho =-0.589, 
P0.0001; magnitude of effort: rho =-0.581, P0.0001), 
the dispersion of BDI subscores for each level of mMRC was 
as wide as for the total score (data not shown).
Univariate determinants of mMrC and BDI scores
Several categorical variables were related to mMRC and 
BDI scores, particularly a low BMI, depression, and severe 
hyperinflation (IC/TLC 25%) (Table 2). In addition, the 
mMRC and BDI scores were both highly correlated with 
SGRQ total score (Table 3). The correlation levels with 
lung function variables appeared similar for mMRC and 
BDI scores. BDI score and subscores were more closely 
correlated with clinical variables (SGRQ and HAD scores) 
than with lung function variables. Among them, the higher 
correlations were observed with FEV
1
, followed by the level 
of hyperinflation as assessed by IC/TLC and FRC/TLC. The 
relationships between mMRC and BDI scores with FRC% 
pred and RV% pred were significantly lower.
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1666
Perez et al
Table 1 Description of patients characteristics by GOLD grade of airflow obstruction
GOLD 1 (N=15) GOLD 2 (N=98) GOLD 3 (N=79) GOLD 4 (N=47)
age (years) 74.0 [47.0; 77.0] 65.0 [56.0; 72.0] 64.0 [57.0; 72.0] 64.0 [57.0; 73]
BMI 25.0 [22.2; 29.7] 25.5 [23.3; 29.3] 24.5 [20.1; 28.3] 22.4 [18.8; 25.7]
FEV1 (% pred) 85.2 [83.7; 90.4] 66.1 [58.8; 72.7] 40.9 [35.0; 44.9] 25.0 [20.6; 29.3]
FVC% pred 118 [109.7; 124.1] 95 [87.4; 103.9] 81.5 [68.6; 92.7] 75.9 [62.9; 123.4]
FrC% pred 128.6 [100.8; 150.5] 122.1 [97.4; 139.9] 153.7 [125.7; 176.4] 179.5 [152.1; 212.7]
RV% pred 148.8 [106.7; 179.8] 132.9 [104.6; 165.4] 183.1 [154.6; 209.6] 223.3 [184.9; 261.7]
IC/TlC 0.37 [0.35; 0.45] 0.39 [0.33; 0.45] 0.28 [0.22; 0.33] 0.23 [0.17; 0.26]
haD anxiety 6.0 [4.0; 10.0] 7.0 [4.0; 11.0] 7.0 [5.0; 10.0] 8.0 [4.0; 11.0]
haD depression 6.0 [2.0; 10.0] 5.0 [3.0; 8.0] 6.0 [3.0; 9.0] 7.0 [3.0; 10.0]
BDI 6 [4; 10] 7 [6; 9] 6 [4; 7] 4 [3; 6]
mMrC 1 [0; 3] 1 [1; 2] 2 [1; 3] 3 [2; 3]
mMrC
grade 0 (%) 4 (27%) 24 (24%) 8 (10%) 1 (2%)
grade 1 (%) 6 (40%) 48 (49%) 23 (29%) 6 (13%)
grade 2 (%) 1 (7%) 15 (15%) 24 (30%) 12 (26%)
grade 3 (%) 3 (20%) 7 (7%) 17 (22%) 18 (38%)
grade 4 (%) 1 (7%) 4 (4%) 7 (9%) 10 (21%)
heart failure (%) 1 (7%) 17 (17%) 12 (15%) 8 (17%)
Venous thromboembolic history (%) 1 (7%) 9 (9%) 6 (8%) 3 (6%)
BMI
18.5 kg/m2 0 1 (1%) 11 (14%) 10 (21%)
30 kg/m2 3 (20%) 21 (21%) 16 (20%) 5 (11%)
Note: Data are shown as median [IQR] or n (%).
Abbreviations: BDI, Baseline Dyspnea Index; BMI, body mass index; GOLD, Global initiative for chronic Obstructive Lung Disease; HAD, Hospital Anxiety-Depression; 
FEV1, forced expiratory volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; IC, inspiratory capacity; IQR, interquartile range; mMRC, modified 
Medical Research Council; RV, residual volume; TLC, total lung capacity.
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Figure 1 Distribution of the BDI score.
Abbreviation: BDI, Baseline Dyspnea Index.
For all variables but BMI, the Spearman correlation 
coefficients were higher with BDI functional impairment, 
lower with BDI magnitude of effort, and intermediate with 
BDI magnitude of task.
Multivariate determinants of mMrC and BDI scores
Our univariate analysis showed a close relationship between 
dyspnea and HRQoL, according to previous studies.11,23 We, 
therefore, deliberately excluded SGRQ from our multivariate 
analysis, to unmask other contributing factors.
The results of ordinal logistic regression for mMRC grade 
and BDI score are shown in Tables 4 and 5; Figures 3 and 4. 
Major determinants (as indicated by high correlation coef-
ficient values) were different for mMRC and BDI scores. For 
both scores, the first covariate was FEV
1
. Other independent 
determinants of both mMRC scale and BDI were exacerba-
tion rate, obesity, heart failure, depression, and IC/TLC. 
Thromboembolic history and denutrition were significantly 
associated with the mMRC scale only.
Altogether, combining all independent determinants of 
dyspnea allowed us to explain only a moderate proportion 
of mMRC and BDI variations.
Discussion
In this cohort of COPD patients with a wide range of air-
flow limitation, mMRC dyspnea grades and BDI scores 
were correlated at the group level. However, for individual 
patients, large variations of BDI scores were observed for 
a given level of mMRC. The IQRs of BDI for each mMRC 
level were between 2 and 4 points, the larger being for 
mMRC 0 and 3. These two measurements shared most, but 
not all, of their determinants, which explained a moderate 
proportion of their variations. These data suggested that 
mMRC and BDI scores explore quite differently the dyspnea 
intensity in COPD patients and thus should ideally be used 
in combination.
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mMrC scale vs BDI
The use of appropriate measurement tools and the understand-
ing of the determinants of dyspnea may help the clinician in 
the management of individual patients. The absence of a gold 
standard to assess dyspnea has to be underlined. Our results 
obtained in a large cohort of stable patients with well-defined 
COPD demonstrate that mMRC scale and BDI may refer to 
markedly different levels of dyspnea severity on an individual 
basis. In the two studies by Mahler et al enrolling 101 and 66 
patients, the correlation coefficients between mMRC and BDI 
scores ranged from 0.61 to 0.73, but no further details were 
provided about the magnitude of discrepancies between these 
tools. Another study comparing the mMRC, BDI, and oxygen 
cost diagram concluded that these tools were equivalent in a 
cross-sectional assessment, as they had the same distribution 
pattern.24 However, in all these studies, concordance at an 
individual level was not investigated or at least not reported. 
The BDI score has the potential advantage of covering several 
sensory components of dyspnea and might confer a more precise 
evaluation of dyspnea intensity and impact on daily life than 
mMRC. The sensitivity of BDI/TDI to longitudinal changes is 
also much higher.13,25 The reasons for marked dispersion of BDI 
scores for a given mMRC dyspnea level (particularly for mMRC 
grades 0 and 3) in our population are difficult to determine.
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Figure 2 Relationships between BDI and mMRC scores in COPD patients. The median value and interquartile range of BDI are indicated for each mMRC level.
Abbreviations: BDI, Baseline Dyspnea Index; COPD, chronic obstructive pulmonary disease; mMRC, modified Medical Research Council.
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Clinical and lung function correlates of dyspnea were very 
similar for both questionnaires, except for thromboembolic 
history and denutrition. However, the proportion of mMRC 
variance explained by these two variables was low and these 
comorbidities were found in only a minority of patients.
Clearly, our results demonstrate that mMRC and BDI 
scores are not interchangeable for the assessment of dyspnea 
in an individual patient. mMRC remains a standard tool 
to evaluate dyspnea in daily practice, and its usefulness is 
highly emphasized in the new GOLD document. Although 
the suggested cut-off to define significant symptoms was 
set at grade 2, recent data suggest that patients with mMRC 
grade 1 may already exhibit a significant impact of COPD, 
as assessed by the COPD assessment test (CAT) score.26 
However, the vast majority of our patients with grade 1 
mMRC had a BDI 5 (Figure 2). The reproducibility of 
mMRC and BDI scores in stable COPD patients have been 
found to be satisfactory,15,20 although it might be less for 
the “classic” BDI than with the self-administered version,12 
which is not available in French at present. The discrepancies 
between BDI and MRC assessments are therefore likely to 
be reproducible, but the present study was not designed to 
answer this question.
Determinants of dyspnea
The second main finding of present study is that FEV
1
, hyper-
inflation, depression, and comorbidities are all major deter-
minants of mMRC and BDI dyspnea scores. Determinants 
of dyspnea remain poorly understood in COPD due to the 
complexity of this symptom and its interindividual variability 
for the same level of physiologic impairment, for instance, 
FEV
1
. The moderate relationship with spirometry has been 
previously found using both mMRC and BDI scores,3 
Table 2 Univariate analysis of categorical variables associated 
with mMRC/BDI
Variables Index Median [IQR] Wilcoxon
P-valueMen Women
sex BDI 6 [5; 8] 6 [3; 8] 0.238
mMrC 1 [1; 3] 2 [1; 3] 0.036
Yes No
Chronic bronchitis BDI 6 [5; 8] 6 [4; 8] 0.699
mMrC 2 [1; 3] 1 [1; 3] 0.567
Venous thromboembolic  
history
BDI 6 [2; 7] 6 [4.5; 8] 0.268
mMrC 3 [1; 3] 1 [1; 3] 0.019
heart failure BDI 5.5 [3; 7] 6 [5; 8] 0.087
mMrC 2 [1; 3] 1 [1; 3] 0.024
low BMI 18.5 kg/m2 BDI 4 [3; 6] 7 [5; 8] 0.0001
mMrC 2 [1; 3] 1 [1; 3] 0.3431
Obesity BDI 6 [5; 8] 6 [4; 8] 0.8822
mMrC 2 [1; 3] 1 [1; 3] 0.5864
HAD 10 HAD 10
anxiety BDI 7 [5; 8] 5.5 [3; 7] 0.003
mMrC 1 [1; 2] 2 [1; 3] 0.001
Depression BDI 7 [5; 8] 4 [3; 6] 0.0001
mMrC 1 [1; 2] 3 [1; 3] 0.00014
25% 25%
IC/TlC BDI 5 [3; 6] 7 [5; 8] 0.0001
mMrC 3 [2; 3] 1 [1; 2] 0.0001
Abbreviations: BDI, Baseline Dyspnea Index; BMI, body mass index; HAD, 
Hospital Anxiety–Depression; IC, inspiratory capacity; IQR, interquartile range; 
mMRC, modified Medical Research Council; TLC, total lung capacity.
Table 3 Univariate analysis of mMRC/BDI correlates, using numerical variables
Spearman correlation coefficients (rho)
mMRC BDI  
total
BDI functional  
impairment
BDI magnitude  
of task
BDI magnitude 
of effort
age rho
P-value
0.10816
0.0953
-0.04967
0.4447
-0.02118
0.7446
-0.01477
0.8203
-0.11339
0.0802
BMI, kg/m2 rho
P-value
-0.04476
0.4910
0.19451
0.0025
0.16882
0.0089
0.21523
0.0008
0.12184
0.0600
SGRQ rho
P-value
0.66602
0.0001
-0.69067
0.0001
-0.65152
0.0001
-0.59262
0.0001
-0.57354
0.0001
haD anxiety rho
P-value
0.19222
0.0028
-0.21341
0.0009
-0.24333
0.0001
-0.17071
0.0082
-0.09802
0.1308
haD depression rho
P-value
0.30348
0.0001
-0.40110
0.0001
-0.41325
0.0001
-0.36808
0.0001
-0.25213
0.0001
FEV1% pred rho
P-value
-0.45100
0.0001
0.40713
0.0001
0.39529
0.0001
0.34706
0.0001
0.27785
0.0001
FVC% pred rho
P-value
-0.26632
0.0001
0.22602
0.0004
0.22084
0.0006
0.20309
0.0016
0.13053
0.0438
IC/TlC% rho
P-value
-0.37503
0.0001
0.33243
0.0001
0.32347
0.0001
0.27679
0.0001
0.20506
0.0014
Abbreviations: BDI, Baseline Dyspnea Index; BMI, body mass index; HAD, Hospital Anxiety–Depression; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; IC, inspiratory capacity; TLC, total lung capacity; mMRC, modified Medical Research Council.
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although overall dyspnea scores deteriorate significantly with 
GOLD stages.15 Our results confirm these data.27,28
In our patients, hyperinflation was a significant determi-
nant of dyspnea, but the correlation was lower than for FEV
1
. 
A few studies have evaluated the relationship between dys-
pnea and the level of resting hyperinflation. Nishimura et al 
recently showed a significant relationship with dyspnea, but 
these authors also found a lower level of correlation than for 
FEV
1
.29 A similar level of correlation with dyspnea intensity 
was found for RV/TLC.24 Our results with IC/TLC confirm 
these findings.
Although dyspnea is classically more severe in COPD 
patients with significant anxiety,6,30 conflicting results have 
been reported recently.31 Notably, factor analysis demonstrated 
that anxiety was found to be a clearly different factor from 
dyspnea.24 Although significant in univariate analysis, anxiety 
was no longer a contributing factor in our multivariate analysis, 
especially after taking into account the level of depression.
Depression is a frequent comorbidity of COPD, although 
its prevalence varies widely among studies.8 The relationship 
between depression and dyspnea has, however, been less 
investigated than for anxiety. Sanchez et al recently performed 
a principal component analysis including dyspnea (MRC and 
BDI), HRQoL, HAD score, and plethysmography data in 
a large population of 328 patients with altered ventilatory 
capacity, including 128 COPD patients. Surprisingly, psycho-
logical status and dyspnea appeared as separate dimensions.28 
The authors hypothesized that BDI and MRC only reflected 
the sensory dimension of dyspnea, thus neglecting its affec-
tive component. Conversely, another study also found that 
depression was a significant contributor to low HRQoL 
(SGRQ) in multivariate analysis.23 In our patients, depression 
appeared much more significantly associated with dyspnea 
assessed by BDI in multivariate analysis than by mMRC. 
Treatment of depression in COPD may improve symptoms 
and HRQoL in COPD patients,32 but randomized studies are 
clearly lacking to evaluate its impact on dyspnea.
Exacerbation rate is significantly associated with dyspnea 
in both mMRC and BDI models. The relation between exac-
erbations and dyspnea is well demonstrated as well as their 
negative impact on HRQoL.23 Our patients were evaluated in 
stable condition, but repeated exacerbations may play a role 
in anticipating forthcoming episodes of increased dyspnea 
and limitation, leading to what can be called “kinesiophobia” 
or dyspnea-related fear.31
The relationship with thromboembolic history was rather 
unexpected since 1) no suspicion of post-embolic pulmonary 
hypertension was found and 2) the prevalence of chronic 
Table 4 Determinants of the mMRC scale in stepwise multivariate analysis
Analysis of maximum likelihood estimates
Parameter Unit DF Estimate Standard error Wald χ2 Pr  χ2
BMI 18.5 kg/m2 Yes 1 0.8422 0.4419 3.6326 0.0567
Obesity Yes 1 -0.6220 0.3150 3.8985 0.0483
FEV1 %pred 1 0.0391 0.00785 24.7789 0.0001
IC/TlC class 25% 1 0.6994 0.3237 4.6689 0.0307
haD depression 10 1 -0.8960 0.3008 8.8746 0.0029
Exacerbations rate n/year 1 -0.1621 0.0547 8.7854 0.0030
heart failure Yes 1 -0.8884 0.3289 7.2974 0.0069
Venous thromboembolic history Yes 1 -1.0541 0.4461 5.5819 0.0181
Abbreviations: BMI, body mass index; DF, degree of freedom; HAD, Hospital Anxiety–Depression; FEV1, forced expiratory volume in 1 second; IC, inspiratory capacity; 
mMRC, modified Medical Research Council; TLC, total lung capacity.
Table 5 Determinants of the BDI total score in stepwise multivariate analysis
Analysis of maximum likelihood estimates
Parameter Unit DF Estimate Standard error Wald χ2 Pr  χ2
Obesity Yes 1 0.5180 0.3077 2.8352 0.0922
FEV1 % pred 1 -0.0252 0.00734 11.7574 0.0006
IC/TlC class 25% 1 -0.5617 0.3177 3.1256 0.0771
haD depression 10 1 1.2797 0.2997 18.2346 0.0001
Exacerbation rate n/year 1 0.1515 0.0537 7.9483 0.0048
heart failure Yes 1 0.7912 0.3243 5.9522 0.0147
Abbreviations: BDI, Baseline Dyspnea Index; DF, degree of freedom; HAD, Hospital Anxiety–Depression; FEV1, forced expiratory volume in 1 second; IC, inspiratory 
capacity; TlC, total lung capacity.
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Figure 3 Determinants of the mMRC grade (stepwise logistic regression).
Abbreviations: BDI, Baseline Dyspnea Index; FEV1, forced expiratory volume in 1 second; IC, inspiratory capacity; mMRC, modified Medical Research Council; TLC, total 
lung capacity.
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Figure 4 Determinants of the BDI score (stepwise logistic regression).
Abbreviations: BDI, Baseline Dyspnea Index; FEV1, forced expiratory volume in 1 
second; IC, inspiratory capacity; TlC, total lung capacity.
post-embolic pulmonary hypertension after a first episode 
was low.33 However, it must be acknowledged that patients 
were not systematically assessed for chronic thromboembolic 
pulmonary hypertension.
Heart failure is a frequent comorbidity in COPD patients 
and plays a role in dyspnea, although it seems difficult to 
determine its precise contribution in individual patients. 
Dyspnea is more severe in patients with systolic heart 
failure and coexisting COPD, and increases with GOLD 
stages.26 We cannot exclude an underdiagnosis of heart 
failure (particularly diastolic) in some patients because of 
the absence of systematic investigations.
Obesity was a contributing factor in both BDI and mMRC 
models. Conversely, it was recently suggested that moderate 
obesity could improve dyspnea during exercise in COPD, 
through its limiting effect on hyperinflation during exercise, 
but this hypothesis remains controversial.34
Higher degrees of dyspnea are often reported in female 
COPD patients for a comparable level of FEV
1
 impairment. 
Such a finding was recently confirmed in our cohort35 after 
a careful matching for age and FEV
1
 level of male vs female 
patients (3:1 ratio). The difference for mMRC grade was 
similar in our subset of patients in univariate analysis (mMRC 
grade 1 in males vs grade 2 in females) but disappeared in 
the multiple regression. This difference is probably related 
to the multivariate analysis per se as well as to sampling 
differences in our cohort between the two studies. 
One important strength of the present study is the sys-
tematic, simultaneous assessment of comprehensive lung 
function variables (including lung volumes) and clinical 
variables. In addition to the simple mMRC scale, we used 
the BDI score, which remains at present the most sensitive 
questionnaire to assess the severity of dyspnea and dyspnea-
related impact on exercise and activity. 
The present study also has some limitations. Our 
patients were recruited in pulmonary clinics of university 
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hospitals, and therefore may not represent the COPD 
population at large, with a lower proportion of stage I 
patients. However, they had a wide range of airflow limi-
tation, indicating various degrees of spirometric severity. 
The emotional aspects of dyspnea were not assessed 
due to the MRC and BDI measuring properties. New 
questionnaires include this dimension and may provide 
additional information about dyspnea components.36,37 
The relationships of these new questionnaires with other 
COPD components or outcomes remain to be confirmed in 
large field studies. Another limitation of the present study 
is that the severity of comorbidities (eg, heart failure) 
was not precisely assessed. Other potential contributing 
lung function parameters were unavailable, particularly 
DL
CO
, inspiratory muscle strength, expiratory flow limi-
tation, and airway resistance. The latter, either assessed 
by plethysmography or forced oscillation, was recently 
shown to correlate significantly with dyspnea in COPD 
patients.38 Exercise capacity and physical activity were 
also not evaluated in our study.
However, dyspnea is likely to be a determinant of exer-
cise tolerance and not the contrary, although regular physi-
cal activity may play a positive role through its impact on 
deconditioning.
Conclusion
In conclusion, this study shows that, although related on 
a statistical ground, mMRC and BDI scores may evaluate 
very differently the dyspnea intensity in individual patients. 
BDI and mMRC scale thus appear complementary, in the 
absence of a gold standard tool. New self-administered 
questionnaires are clearly needed, evaluating both sensory 
and affective components of dyspnea. These questionnaires 
should also be highly sensitive to changes, particularly 
therapeutic interventions. Present results also confirm the 
complexity of dyspnea determinants in COPD and suggest 
a significant impact of frequent exacerbations, hyperinfla-
tion, and common comorbidities, particularly heart failure 
and depression.
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